Ad-hoc | 26 May 2016 07:00
Kuros Biosciences Invites to the Annual Shareholders’ Meeting 2016
|
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): AGM/EGM
Kuros Invites to the Annual Shareholders’ Meeting 2016 Schlieren (Zurich), Switzerland, May 26, 2016 – Kuros Biosciences Ltd (“Kuros”) today announced that the Annual Shareholders’ Meeting 2016 will take place on Thursday, June 16, 2016 at 1 p.m. at the Company’s offices in Schlieren/Zurich (Switzerland). The Board of Directors proposes to carry out a reverse stock split at the ratio of 100 to 1 and to amend the Articles of Association accordingly. The capital restructuring measures in 2015 and 2016 resulted in a nominal value of CHF 0.01 per registered share. To simplify the trading and to increase the shares’ attractiveness for investors, the Board proposes to carry out a reverse stock split at the ratio of 100 to 1 with the effect that 100 registered shares with a nominal value of CHF 0.01 each will be exchanged into 1 new (merged) registered share with a nominal value of CHF 1.00. The current shareholders and founders Dr. Jeffrey Hubbell and Didier Cowling have committed for no consideration to providing the other shareholders with the number of shares required in connection with the reverse stock split to enable the allocation of a rounded number of shares to every shareholder. As a result, each existing shareholder will receive at least one share and in any event, a rounded number of shares. The nominal value of the shares that may be issued under the conditional and the authorized capital is to be changed from CHF 0.01 to CHF 1.00 as well to enable the future issuance of a round number of shares. Messrs Dominik Ellenrieder and Vincent Ossipow do not stand for re-election as member of the Board. The Board of Directors proposes to elect Leanna Caron as new member of the Board. Mrs Caron is Executive Vice President and Chief Commercial Officer for AgNovos Healthcare. A healthcare executive for the past 20 years, she developed an acumen in business development, strategic planning and partnerships, global marketing, and overall business management. Mrs Caron received her Pharmacy degree from the University of Toronto and her MBA from Concordia and Cornell Universities. The formal invitation to the meeting will be sent out within the next few days and can also be downloaded from the following website http://www.kuros.ch/uploads/2016/AGM2016.pdf
For further information, please contact:
About Kuros Biosciences Ltd Kuros Biosciences Ltd is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol KURN. Information regarding Kuros is available at www.kuros.ch .
Forward Looking Statements
End of ad hoc announcement Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=XTVBJJSLJH Document title: Kuros_AGM Invitation 2016-05-26 News transmitted by Tensid EQS AG. www.eqs.com The issuer is responsible for the contents of the release. |
| Language: | English | |
| Company: | Kuros Biosciences AG | |
| Wagistrasse 25 | ||
| 8952 Schlieren | ||
| Switzerland | ||
| Phone: | +41 44 733 4747 | |
| Fax: | +41 44 733 4740 | |
| E-mail: | info@kuros.ch | |
| Internet: | www.kuros.ch | |
| ISIN: | CH0011025217 | |
| Valor: | – | |
| Listed: | Foreign Exchange(s) SIX | |
| End of News | EQS Group News Service |